Last reviewed · How we verify
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A (Copper Cu 64 Anti-CEA Monoclonal Antibody M5A) — City of Hope Medical Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Copper Cu 64 Anti-CEA Monoclonal Antibody M5A TARGET | Copper Cu 64 Anti-CEA Monoclonal Antibody M5A | City of Hope Medical Center | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Copper Cu 64 Anti-CEA Monoclonal Antibody M5A CI watch — RSS
- Copper Cu 64 Anti-CEA Monoclonal Antibody M5A CI watch — Atom
- Copper Cu 64 Anti-CEA Monoclonal Antibody M5A CI watch — JSON
- Copper Cu 64 Anti-CEA Monoclonal Antibody M5A alone — RSS
Cite this brief
Drug Landscape (2026). Copper Cu 64 Anti-CEA Monoclonal Antibody M5A — Competitive Intelligence Brief. https://druglandscape.com/ci/copper-cu-64-anti-cea-monoclonal-antibody-m5a. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab